The Latest Breaking News on Pharma

Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.

Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.

Even though Amgen is weak below the 200-day line, there's still a way to profit.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

The drugs-control-administration">Drugs Control Administration, Telangana, seized a huge stock of antibiotics worth Rs 1.33 Crores from a manufacturing facility on Wednesday. Read further on Dynamite News:

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

AMD stock faces bearish wave, below key moving averages with neutral RSI. Short-term rebound possible, but overall technicals and market share gains uncertain.

ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level.